

SPH.L

Posting of Circular and Notice of General Meeting

Sinclair Pharma plc (SPH:L), the international specialty pharma company, announces that it has posted to shareholders a circular concerning the Sinclair 2011 Value Creation Plan with notice of a general meeting which is to be held at the offices of Fasken Martineau LLP, 17 Hanover Square, London, W1S 1HU on 13th January 2011 at 10.00 a.m.

The Board strongly believes that it can create substantial value for shareholders over the medium to long term through building and strengthening the Company's position. The Company expects to take advantage of significant developments in its business plan and making best use of this opportunity will be highly dependent on the performance of the Key Executives.

The Remuneration Committee (the Committee) recently undertook a detailed review of its current policy to ensure that it supports these business objectives and that it continues to attract, motivate and retain individuals who are critical to executing the business strategy and delivering exceptional growth in shareholder value.

It is the Committee's opinion, that the existing Employee Incentive Plan should be replaced by a new incentive arrangement, the Sinclair Pharma Plc 2011 Value Creation Plan.

Value Creation Plan

Under the VCP, participants will be allocated a number of units from a total pot. These units have no value on grant but give the participants the opportunity, during the five year performance period, to share in a proportion of the total value created for shareholders depending on level of value created compared to an annual hurdle at a series of annual measurement dates ("Measurement Dates"). The annual hurdle is a minimum growth of total shareholder return of 20% p.a. above which participants will receive 15% of the value created.

Copies of the Circular and Notice of General Meeting are available on the company's investor relations website at www.sinclairpharma.com. Copies of the Notice of General Meeting have been submitted to the National Storage Mechanism and will shortly be available for viewing at www.hemscott.com/nsm.do.

For further information please contact:

Sinclair Pharma plc
Christopher Spooner, CEO
Alan Olby, CFO

Tel: +44 (0)1483 410 600

Singer Capital Markets Ltd
Shaun Dobson
Claes Spång

Tel: +44 (0)20 3205 7500

Financial Dynamics
Ben Atwell, Stephanie Cuthbert

Tel: +44 (0)20 7831 3113

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is present in France, Italy, Germany and Spain, and an extensive marketing partner network across selected developed & emerging markets.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.